



Telix Receives \$9.3m R&D Tax Refund

Melbourne (Australia) – 18 July 2019. Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) announces that it has received a AUD \$9.3m R&D tax rebate for eligible domestic and international R&D activities undertaken in the year ended 31 December 2018.

On 3 August 2018 the Company announced it had received an ‘advance finding’ from the Department of Innovation, Industry and Science in relation to its proposed pre-clinical, clinical, manufacturing and regulatory-related activities. The advance finding enables the Company to claim R&D tax rebate on eligible domestic and international R&D investment up to a gross amount of \$55.2 million over five years.

The receipt of notice of funds into the Company’s tax account was received on 26 June 2019. Today’s clearing of funds into the Company’s cash account follows an integrity check.

Telix Chairman H. Kevin McCann stated, “The Federal R&D tax credit scheme continues to be vitally important in enabling Telix to pursue its multiple clinical development programs and research partnerships in Australia and abroad. We are appreciative of this support from the Department of Industry, Innovation and Science.”

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited (Telix) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.

Telix Corporate Contact

Dr Christian Behrenbruch
Telix Pharmaceuticals Limited
CEO
Email: chris@telixpharma.com

Telix Investor Relations

Lisa Wilson
In-Site Communications
Tel: +1 212 452 2793
Email: lwilson@insitecony.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “US Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available. None of the products described in this release have obtained a marketing authorisation in any jurisdiction.